Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Corcept Therapeutics Incorporated before investing.

In this article, we go over a few key elements for understanding Corcept Therapeutics Incorporated’s stock price such as:

• Corcept Therapeutics Incorporated’s current stock price and volume
• Why Corcept Therapeutics Incorporated’s stock price changed recently
• Upgrades and downgrades for CORT from analysts
• CORT’s stock price momentum as measured by its relative strength

About Corcept Therapeutics Incorporated (CORT)

Before we jump into Corcept Therapeutics Incorporated’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.

Want to learn more about Corcept Therapeutics Incorporated’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Corcept Therapeutics Incorporated.

Corcept Therapeutics Incorporated’s Stock Price as of Market Close

As of June 10, 2024, 4:00 PM, CST, Corcept Therapeutics Incorporated’s stock price was $31.93.

Corcept Therapeutics Incorporated is down 4.14% from its previous closing price of $33.31.

During the last market session, Corcept Therapeutics Incorporated’s stock traded between $33.11 and $34.30. Currently, there are 102.79 million shares of Corcept Therapeutics Incorporated stock available for purchase.

Corcept Therapeutics Incorporated’s price-earnings (P/E) ratio is currently at 31.2, which is high compared to the Pharmaceuticals industry median of 23.1. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Corcept Therapeutics Incorporated Stock Price History

Corcept Therapeutics Incorporated’s (CORT) price is currently up 5.83% so far this month.

During the month of June, Corcept Therapeutics Incorporated’s stock price has reached a high of $35.22 and a low of $29.88.

Over the last year, Corcept Therapeutics Incorporated has hit prices as high as $35.22 and as low as $20.84. Year to date, Corcept Therapeutics Incorporated’s stock is up 57.21%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Corcept Therapeutics Incorporated Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 07, 2024, there were 3 analysts who downgraded Corcept Therapeutics Incorporated’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Corcept Therapeutics Incorporated’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Corcept Therapeutics Incorporated’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Corcept Therapeutics Incorporated’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Corcept Therapeutics Incorporated (CORT) by visiting AAII Stock Evaluator.

Relative Price Strength of Corcept Therapeutics Incorporated

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 07, 2024, Corcept Therapeutics Incorporated has a weighted four-quarter relative price strength of 11.72%, which translates to a Momentum Score of 90 and is considered to be Very Strong.

Want to learn more about how Corcept Therapeutics Incorporated is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Corcept Therapeutics Incorporated Stock Price: Bottom Line

As of June 10, 2024, Corcept Therapeutics Incorporated’s stock price is $31.93, which is down 4.14% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Corcept Therapeutics Incorporated stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.